指南与共识

1型糖尿病患者辅助使用GLP-1及双重GLP-1/GIP受体激动剂:共识报告与安全使用实践指南

Adjunctive Treatment with GLP-1 and Dual GLP-1/GIP Receptor Agonists for People with Type 1 Diabetes: Consensus Report and Practical Guidelines for Safe Use
RSS 订阅 · 指南共识 · 呼吸支持与睡眠 · 2026-06-05

该共识报告由多个专业协会认可,回顾现有文献,为1型糖尿病患者辅助使用GLP-1及GLP-1/GIP受体激动剂提供安全使用指南。目前这些药物尚未获批用于1型糖尿病,潜在安全风险包括低血糖和高血糖相关酮症,较大规模随机对照试验正在进行或计划中。

要点

  • GLP-1及GLP-1/GIP受体激动剂尚未获批用于1型糖尿病。
  • 1型糖尿病起始此类药物后潜在风险包括低血糖和高血糖相关酮症。
  • 共识旨在促进1型糖尿病患者安全使用此类药物并优化胰岛素剂量调整。

核心结论

  • 该共识报告回顾当前文献,为糖尿病临床医生和1型糖尿病患者提供GLP-1/GIP受体激动剂安全使用的指南。

研究设计与样本

  • 共识报告由ATTD、International Diabetes Federation-Europe、AACE、Breakthrough T1D、ISPAD、ADCES认可。

主要发现

  • 自2005年艾塞那肽引入以来,GLP-1受体激动剂及GLP-1/GIP受体激动剂已改变2型糖尿病管理,但尚未获批用于1型糖尿病。
  • 1型糖尿病中关于此类药物血糖影响的随机对照试验和真实世界研究数量有限、结果不一致且规模小,较大规模随机对照试验正在进行或计划中。
  • 1型糖尿病起始GLP-1/GIP受体激动剂后的潜在安全风险包括低血糖和高血糖相关酮症。

局限性

  • 1型糖尿病中关于此类药物血糖影响的随机对照试验和真实世界研究数量有限、结果不一致且规模小。
  • 1型糖尿病适应症尚未获得监管批准,可能限制患者获取药物及接受安全性教育的机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetes Technol Ther. 2026 Jun 5:15209156261449879. doi: 10.1177/15209156261449879. Online ahead of print. ABSTRACT Among the most impactful therapeutic advances in the management of diabetes over the past two decades has been the development of incretin-based therapies, specifically glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and in combination with glucose-dependent insulinotropic polypeptide (GIP) RAs. Since the introduction of exenatide in 2005, a growing number of these drugs has transformed the management of type 2 diabetes (T2D). Their pleiotropic effects include weight loss, reduced insulin resistance, improved glucose regulation, and reductions in known risk markers for diabetic kidney disease and cardiovascular disease. To date, these important noninsulin glucose-lowering therapies have only received regulatory approval for use in T2D, obesity, sleep apnea, and metabolic dysfunction-associated steatohepatitis with moderate-advanced fibrosis, supported by randomized controlled trials (RCTs) and real-world data that demonstrate efficacy and safety. Regulatory approval for use of weekly GLP-1 and GLP-1/GIP RAs in type 1 diabetes (T1D) has not yet been achieved, in part because of the limited number of inconsistent, small-scale, RCTs and real-world studies for glycemic impacts of these agents in T1D. Larger RCTs are ongoing or planned in participants with T1D. Potential safety risks include hypoglycemia and hyperglycemia-related ketosis in T1D after initiation of GLP-1/GIP RA drugs. While RCTs are ongoing to further investigate GLP-1 and GLP-1/GIP RA agents as adjunct therapy for people with T1D, access to these drugs is already possible, based on their use to treat overweight and obesity. However, without regulatory approval for the T1D indication, access and opportunities for people with T1D to engage with important education regarding the safety of GLP-1 and GLP-1/GIP RA therapy may be limited. This precludes support from diabetes health care professionals to optimize diabetes management of these agents alongside expected insulin dose changes. The purpose of this consensus report is to review the current literature and provide guidelines for diabetes clinicians and people with T1D to facilitate the safe use of GLP-1/GIP RAs in the management of T1D. This consensus statement has been endorsed by the following professional associations: Advanced Technologies & Treatments for Diabetes (ATTD), International Diabetes Federation-Europe, American Association of Clinical Endocrinologists (AACE), Breakthrough T1D, International Society for Pediatric and Adolescent Diabetes (ISPAD), Association of Diabetes Care and Education Specialists (ADCES).

来源:指南共识 · 呼吸支持与睡眠,查看原文。版权归原作者所有。

引用

  1. 指南共识 · 呼吸支持与睡眠:Adjunctive Treatment with GLP-1 and Dual GLP-1/GIP Receptor Agonists for People with Type 1 Diabetes: Consensus Report and Practical Guidelines for Safe Use

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。